Amicus Therapeutics (NASDAQ:FOLD) announces that the European Medicines Agency has granted priority medicines designation to AT-GTX-501, investigational gene therapy for children living with variant late infantile neuronal ceroid lipofuscinosis 6 (vLINCL6) disease, also known as CLN6 Batten disease.
The PRIME designation is based on data from the ongoing Phase 1/2 clinical trial evaluating a single dose of AT-GTX-501 for the treatment of children with CLN6 Batten disease.
Additional data from the ongoing Phase 1/2 clinical study will be presented at the Child Neurology Society Annual Meeting in October.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.